Case number: 1:16-bk-10890 - Defined Diagnostics, LLC - New York Southern Bankruptcy Court

Case Information
  • Case title

    Defined Diagnostics, LLC

  • Court

    New York Southern (nysbke)

  • Chapter

    11

  • Judge

    Michael E. Wiles

  • Filed

    04/12/2016

  • Last Filing

    06/20/2016

  • Asset

    Yes

  • Vol

    v

Docket Header
MDisCs



U.S. Bankruptcy Court
Southern District of New York (Manhattan)
Bankruptcy Petition #: 16-10890-mew

Assigned to: Judge Michael E. Wiles
Chapter 11
Voluntary
Asset


Date filed:  04/12/2016
341 meeting:  05/16/2016

Debtor

Defined Diagnostics, LLC

930 Clopper Road
Gaithersburg, MD 20878
MONTGOMERY-MD
Tax ID / EIN: 26-0310344
fka
32 Mott Street Acquisition II, LLC

fka
Wellstat Diagonostics, LLC

fka
Wellstat Diagnostics, LLC


represented by
Matthew Freimuth

Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, NY 10019
212-728-8183
Fax : 212-728-8111
Email: mfreimuth@willkie.com

Joseph G. Minias

Willkie Farr & Gallagher, LLP
787 7th Avenue
New York, NY 10019-6099
(212) 728-8000
Fax : (212) 728-8111
Email: maosbny@willkie.com

Paul V. Shalhoub

Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, NY 10019-6099
(212) 728-8764
Fax : (212) 728-8111
Email: maosbny@willkie.com

U.S. Trustee

United States Trustee

Office of the United States Trustee
U.S. Federal Office Building
201 Varick Street, Room 1006
New York, NY 10014
(212) 510-0500
 
 

Latest Dockets

Date Filed#Docket Text
06/18/201670Certificate of Mailing Re: Inter-District Transfer (related document(s) (Related Doc # 69)) . Notice Date 06/18/2016. (Admin.) (Entered: 06/19/2016)
06/16/201669Notice of Inter-District Transfer to United States Bankruptcy Court District Of Delaware, Under Case Number 16-11491. (Rodriguez, Maria). (Entered: 06/16/2016)
06/15/201668Order signed on 6/15/2016 transferring case to the District of Delaware due to improper venue. (DePierola, Jacqueline) (Entered: 06/15/2016)
06/10/201667Affidavit of Serviceof Rebecca B. Cordy(related document(s) 62, 59) Filed by Paul V. Shalhoub on behalf of Defined Diagnostics, LLC. (Shalhoub, Paul) (Entered: 06/10/2016)
06/09/201666Transcript regarding Hearing Held on 06/08/16 at 10:16 am RE: PDL BioPharma, Inc.'s objection to use of cash collateral and statement on non-consent to surcharge of collateral Request by PDL BioPharma, Inc. for judicial notice.
Remote electronic access to the transcript is restricted until 9/7/2016.
The transcript may be viewed at the Bankruptcy Court Clerks Office. [Transcription Service Agency: eScribers, LLC.]. (See the Courts Website for contact information for the Transcription Service Agency.). Notice of Intent to Request Redaction Deadline Due By 6/16/2016. Statement of Redaction Request Due By 6/30/2016. Redacted Transcript Submission Due By 7/11/2016. Transcript access will be restricted through 9/7/2016. (Brown, Tenille) (Entered: 06/10/2016)
06/07/201665Affidavit of Service (related document(s) 61, 60) Filed by Matthew K. Kelsey on behalf of PDL Biopharma, Inc.. (Kelsey, Matthew) (Entered: 06/07/2016)
06/07/201664Affidavit of Serviceof Alison R. Ambeault(related document(s) 58) Filed by Joseph G. Minias on behalf of Defined Diagnostics, LLC. (Minias, Joseph) (Entered: 06/07/2016)
06/07/201663Affidavit of Serviceof Alison R. Ambeault(related document(s) 53, 49, 52, 51, 50) Filed by Joseph G. Minias on behalf of Defined Diagnostics, LLC. (Minias, Joseph) (Entered: 06/07/2016)
06/07/201662Notice of Agendaof Matters Scheduled for Hearing on June 8, 2016 at 10:00 A.M. (Eastern Time)filed by Joseph G. Minias on behalf of Defined Diagnostics, LLC. with hearing to be held on 6/8/2016 at 10:00 AM at Courtroom 617 (MEW) (Minias, Joseph) (Entered: 06/07/2016)
06/06/201661Declarationof Matthew K. Kelsey in Support of PDL Biopharma Inc.'s Omnibus Reply in Support of its (I) Motion to Dismiss the Chapter 11 Case of Defined Diagnostics, LLC (II) Motion for Excusal from Turnover Requirement and (III) Objection to Use of Cash Collateral and Surcharge(related document(s) 60) filed by Matthew K. Kelsey on behalf of PDL Biopharma, Inc.. (Kelsey, Matthew) (Entered: 06/06/2016)